A modest reduction in c-Myc expression has minimal effects on cell growth anti apoptosis but dramatically reduces susceptibility to Ras and Raf transformation

Cancer Research

Volumn 61, Issue 3, 2001, Pages 1178-1186

  Bazaro, Alex V ^a,b   Adachi, Susumu ^a,c   Li, Sheng Feng ^d   Mateyak, Maria K ^a   Wei, Shan ^a   Sedivy, John M ^a  

^a BROWN UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIN A; CYCLIN D1; PROTEIN P27; RAF PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; DNA FLANKING REGION; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENETIC RECOMBINATION; GENETIC SUSCEPTIBILITY; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE C MYC; ONCOGENE RAS; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

ANIMALS; APOPTOSIS; CELL ADHESION; CELL CYCLE PROTEINS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DOWN-REGULATION; FIBROBLASTS; GENE SILENCING; GENES, MYC; MICROTUBULE-ASSOCIATED PROTEINS; ONCOGENE PROTEINS V-RAF; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; RATS; RATS, MUTANT STRAINS; RETROVIRIDAE PROTEINS, ONCOGENIC; TUMOR SUPPRESSOR PROTEINS;

EID: 0035118130     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Anchorage and growth regulation in normal and virus-transformed cells
2. Cellular tumorigenicity in nude mice: Correlation with cell growth in semi-solid medium
3. Agar suspension culture for the selective assay of cells transformed by polyoma virus
4. The control of mRNA production, translation and turnover in suspended and reattached anchorage-dependent fibroblasts
5. Progressive loss of shape-responsive metabolic controls in cells with increasingly transformed phenotype
6. Tumorigenicity of virustransformed cells in nude mice is correlated specifically with anchorage independent growth in vitro
7. Role of cell shape in growth control
8. Anchorage-dependent cell cycle progression
9. Cytoskeletal integrity is required throughout the mitogen stimulation phase of the cell cycle and mediates the anchorage-dependent expression of cyclin D1
10. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein
11. Dependence of cyclin E-cdk2 kinase activity on cell anchorage
12. Ras induces anchorage-independent growth by subverting multiple adhesion-regulated cell cycle events
13. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site
14. Anchorage-dependent transcription of the cyclin A gene
15. A link between cyclin A expression and adhesion-dependent cell cycle progression
16. Integrin-mediated cell adhesion activates mitogen-activated protein kinases
17. Matrix/integrin interaction activates the mitogen-activated protein kinase p44erk-1 and p42erk-2
18. Integrin-dependent activation of MAP kinase: A link to shape-dependent cell proliferation
19. Cell anchorage permits efficient signal transduction between Ras and its downstream kinases
20. Growth factor activation of MAP kinase requires cell adhesion
21. Adhesion-dependent control of cyclin E/cdk2 activity and cell cycle progression in normal but not in Ha-ras transformed NRK cells
22. Ras signals to the cell cycle machinery via multiple pathways to induce anchorage-independent growth
23. Multiple Ras functions can contribute to mammalian cell transformation
24. Proteins of the Myc network: Essential regulators of cell growth and differentiation
25. Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts
26. Cellular oncogenesis and multistep carcinogenesis
27. Rapid induction of an experimental metastatic phenotype in first passage rat embryo cells by cotransfection of EJ c-Ha-ras and c-myc oncogenes
28. Synergism of v-myc and v-ras in the in vitro neoplastic progression of murine lymphoid cells
29. Absence of p53 allows direct immortalization of hematopoietic cells by the myc and ras oncogenes
30. Cooperative effects of v-myc and c-Ha-ras oncogenes on gap junctional intercellular communication and tumorigenicity in rat liver epithelial cells
31. Effects of c-myc expression on proliferation, quiescence, and G0 to G1 transition in nontransformed cells
32. Effects of c-myc expression on cell cycle progression
33. Phenotypes of c-Myc-deficient Rat fibroblasts isolated by targeted homologous recombination
34. A cell culture model system for genetic analyses of the cell cycle by targeted homologous recombination
35. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus
36. Use of retroviral vectors for gene transfer and expression
37. Dominant negative MYC blocks transformation by ABL oncogenes
38. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points
39. A preparative suspension culture system permitting quantitation of anchorage-independent growth by direct radiolabeling of cellular DNA
40. Oncogenic signal-induced ability to enter S phase in the absence of anchorage is the mechanism for the growth of transformed NRK cells in soft agar
41. Probing structure and function of the raf protein kinase domain with monoclonal antibodies
42. Cyclin A links c-Myc to adhesion-independent proliferation
43. Induction of p27/Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway
44. Induction of apoptosis in fibroblasts by c-myc protein
45. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines
46. Neoplastic transformation by the human gene N-myc
47. Cyclins and cancer
48. Participation of cyclin A in Myc-induced apoptosis
49. Ectopic expression of cyclin D1 but not cyclin E induces anchorage-independent cell cycle progression
50. Cyclin E-CDK2 is a regulator of p27Kip1
51. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc
52. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27/KIP1
53. Ras activity late in G1 phase is required for p27kip1 downregulation, passage through the restriction point, and entry into S-phase in growth factor stimulated NIH 3T3 fibroblasts
54. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes
55. Requirement of p27/KIP1 for restriction point control of the fibroblast cell cycle
56. Myc-enhanced expression of Cull protein promotes ubiquitin-dependent proteolysis and cell cycle progression
57. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
58. Identification of CDK4 as a target of c-MYC
59. The murine gene p27/KIP1 is haplo-insufficient for tumor suppression
60. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology
61. Direct activation of TERT transcription by c-MYC
62. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation
63. Tumor surveillance via the ARF-p53 pathway
64. INK4a
65. The p21(WAF1/C1P1) promoter is methylated in Rat-1 cells: Stable restoration of p53-dependent p21(WAF1/C1P1) expression after transfection of a genomic clone containing the p21(WAF1/C1P1) gene
66. Creation of human tumor cells with defined genetic elements
67. Cell cycle targets of Ras/Raf signaling
68. Senescence of human fibroblasts induced by oncogenic Raf
69. Increased proteasome-dependent degradation of cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
70. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
71. Antisense strategy in hematological malignancies
72. Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide
73. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model